Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Canada Goose Reports Results for Fiscal Year 2019 – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Canada Goose Reports Results for Fiscal Year 2019

Published

on

Reading Time: 13 minutes

Fiscal 2019 Highlights (in millions of Canadian dollars):

  • Total revenue increased by 40.5% to $830.5m
  • Net income was $143.6m, or $1.28 per diluted share
  • Adjusted EBITDA margin expanded by 240 basis points to 27.6%
  • Adjusted net income per diluted share increased by 61.9% to $1.36

Adjusted EBITDA margin and adjusted net income per diluted share are
non-IFRS financial measures. See “Note Regarding Non-IFRS Financial
Measures”.

TORONTO–(BUSINESS WIRE)–Canada Goose Holdings Inc. (“Canada Goose” or the “Company”) (NYSE:GOOS,
TSX:GOOS) today announced financial results for the fourth quarter and
fiscal year ended March 31, 2019. The Annual Report, including
Management’s Discussion and Analysis and Audited Consolidated Financial
Statements, will be filed on SEDAR at www.sedar.com,
the EDGAR section of the U.S. Securities and Exchange Commission website
at www.sec.gov.
and posted on the Company’s web site at investor.canadagoose.com.

“I am extremely proud of Canada Goose’s many strategic accomplishments
in fiscal 2019. We entered the year with a very ambitious agenda of
global growth, and we have surpassed it with flying colours,” said Dani
Reiss, President & CEO. “We have come a long way in a short time and we
have done it the right way – by preserving the purity of our brand and
building for the future. Our business and our people have never been
stronger. I believe that we are still just scratching the surface of our
long-term potential as we continue to define performance luxury
globally.”

Fiscal 2019 Business Highlights

Advertisement
Stake.com
  • Growth in every geographic region, with annual revenue increasing by
    28.2% in Canada, 36.3% in the United States and 60.5% in Rest of World.
  • Successfully launched DTC operations in Greater China, the world’s
    largest luxury market.
  • Proportion of total revenue generated in Rest of World (34.5%) was
    in-line with Canada (35.3%) for the first time.
  • Global footprint of 11 directly-operated retail stores and 12 national
    e-commerce markets increased DTC sales to over half of total revenue
    at 51.9%.
  • Established new generations of hero products in nascent rainwear and
    knitwear categories, alongside continued innovation in parkas and
    lightweight down collections.
  • Acquired Baffin, which will provide valuable expertise and
    infrastructure to develop a stand-alone Canada Goose footwear offering
    in the years to come.
  • Eight in-house manufacturing facilities, including two opened during
    the year, produced 47% of total down-filled jacket volume.

Fiscal 2019 Results (in Canadian dollars, compared to Fiscal 2018):

  • Total revenue increased by 40.5% to $830.5m from $591.2m, or 39.0% on
    a constant currency basis(1).
  • Wholesale revenue increased to $399.2m from $336.2m. This was driven
    by higher order values from existing partners. Incremental revenue
    from Baffin, which was acquired in November 2018, and favourable
    foreign exchange fluctuations also contributed positively.
  • DTC revenue increased to $431.3m from $255.0m, representing 51.9% of
    total revenue compared to 43.1%. The increase was primarily
    attributable to incremental revenue from five new retail stores and
    one new e-commerce market. This was complemented by strong
    performances from established e-commerce markets and retail stores.
  • Gross profit increased to $516.8m, a gross margin of 62.2%, compared
    to $347.6m, a gross margin of 58.8%. The increase in gross margin was
    driven by a greater proportion of DTC revenue, and to a lesser degree,
    incremental gross margin expansion at the respective channel levels.
  • DTC gross profit was $324.6m, a gross margin of 75.3%, compared to
    $189.8m, a gross margin of 74.4%. The increase in gross margin was
    primarily driven by pricing, partially offset by manufacturing labour
    cost increases.
  • Wholesale gross profit was $192.2m, a gross margin of 48.1%, compared
    to $157.8m, a gross margin of 46.9%. The increase in gross margin was
    primarily attributable to pricing, partially offset by manufacturing
    labour cost increases. To a lesser degree, wholesale gross margin also
    benefitted from production efficiencies in manufacturing overhead,
    partially offset by changes in product mix.
  • Operating income was $196.7m, compared to $138.1m. The increase in
    operating income was driven by revenue growth and gross margin
    expansion, partially offset by SG&A growth investments.
  • Unallocated corporate expenses were $169.1m, compared to $107.8m. The
    increase was primarily due to investments to support growth in
    marketing, corporate headcount and IT, including Greater China
    operations. Professional fees and other costs relating to public
    company compliance also increased.
  • Unallocated depreciation and amortization was $18.0m, compared to
    $9.4m, driven by the retail store opening program.
  • DTC operating income was $234.6m, an operating margin of 54.4%,
    compared to $134.7m, an operating margin of 52.8%. This was driven by
    gross margin expansion, strong sales productivity across the channel
    and lower pre-opening costs, partially offset by incremental SG&A fees
    to operating partners in Greater China.
  • Wholesale operating income was $149.2m, an operating margin of 37.3%,
    compared to $120.6m, an operating margin of 35.9%. The increase in
    operating margin was largely driven by gross margin expansion.
  • Net income was $143.6m, or $1.28 per diluted share, compared to
    $96.1m, or $0.86 per diluted share. The increase in net income was due
    to higher operating income and a lower effective tax rate.
  • Adjusted EBITDA(1) was $229.6m, a margin of 27.6%, compared
    to $149.2m, a margin of 25.2%.
  • Adjusted EBIT(1) was $206.9m, a margin of 24.9%, compared
    to $136.4m, a margin of 23.1%.
  • Adjusted net income(1) was $151.6m, or $1.36 per diluted
    share, compared to adjusted net income(1) of $94.1m, or
    $0.84 per diluted share.

(1) See “Note Regarding Non-IFRS Financial Measures”.

Launch of Normal Course Issuer Bid

The board of directors of the Company has authorized a normal course
issuer bid (the “NCIB”) to purchase for cancellation up to 1,600,000
subordinate voting shares of Canada Goose over the twelve-month period
commencing on May 31, 2019 and ending no later than May 30, 2020,
representing approximately 2.70% of the 59,151,443 subordinate voting
shares issued and outstanding as at May 17, 2019. The NCIB will be
conducted through the facilities of the Toronto Stock Exchange (the
“TSX”) and the New York Stock Exchange (the “NYSE”) or alternative
trading systems, if eligible, and will conform to their
regulations. Subordinate voting shares will be acquired under the NCIB
at the market price plus brokerage fees. Purchases under the NCIB will
be made by means of open market transactions or such other means as a
securities regulatory authority may permit. In the event that the
Company acquires subordinate voting shares by other means as a
securities regulatory authority may permit, the purchase price of the
subordinate voting shares may be different than the market price of the
subordinate voting shares at the time of the acquisition. Purchases made
under an issuer bid exemption order will be at a discount to the
prevailing market price as per the terms of the order. Furthermore,
under the NCIB, Canada Goose may make, once per week, a block purchase
(as such term is defined in the TSX Company Manual) at market price, in
accordance with TSX rules. Under TSX rules, block purchases may not be
made, directly or indirectly, from any insider of the Company, including
any funds managed by Bain Capital. Canada Goose will otherwise be
allowed to purchase daily, through the facilities of the TSX, a maximum
of 131,422 subordinate voting shares representing 25% of the average
daily trading volume, as calculated per the TSX rules for the six-month
period starting on November 1, 2018 and ending on April 30, 2019.

Canada Goose currently believes that the purchase of the Company’s
subordinate voting shares under the NCIB is an appropriate and desirable
use of available excess cash.

Canada Goose has not repurchased any of its outstanding subordinate
voting shares under a normal course issuer bid in the past 12 months.

IFRS 16

Advertisement
Stake.com

The Company will adopt IFRS 16, a new standard for lease accounting
which replaces IAS 17, on April 1, 2019. The standard requires
substantially all assets obtained through operating leases to be
capitalized and a related liability to be recorded. The nature and
timing of expenses will also change as IFRS 16 replaces straight-line
operating lease expense with a depreciation charge for right-of-use
assets and interest expense on lease liabilities.

As a result, the Company will replace Adjusted EBITDA and Adjusted
EBITDA margin with Adjusted EBIT and Adjusted EBIT margin in its
supplementary non-IFRS measures and financial outlook. With the
capitalization of operating leases and the movement of lease expenses to
depreciation and interest, management believes that Adjusted EBITDA will
no longer be a meaningful supplemental measure to assess operating
profit and operating profitability. Further details regarding IFRS 16
are provided in Management’s Discussion and Analysis in the Annual
Report.

Fiscal Year 2020 and Long-Term Outlook

For fiscal 2020, the Company currently expects the following:

  • Annual revenue growth of at least 20%
  • Adjusted EBIT margin expansion of at least 40 basis points
  • Annual growth in adjusted net income per diluted share of at least 25%

Key assumptions underlying the fiscal 2020 outlook above are as follows:

  • Wholesale revenue growth in the high-single-digits on a percentage
    basis
  • Eight new retail stores in operation by the end of the winter selling
    season
  • One new digital concept store in operation by the end of the winter
    selling season, which will be an experiential showroom to drive local
    e-commerce sales in the Greater Toronto Area. It is not expected to
    generate revenue or operating income at a level consistent with the
    Company’s traditional retail store format.
  • Materially larger losses in adjusted EBIT and adjusted net income per
    diluted share during the fiscal first quarter, due to a larger number
    of retail stores operating during off-peak periods and higher
    corporate SG&A investments to support growth, including local market
    activation ahead of planned retail openings, new product and Greater
    China operations.
  • Capital expenditures of $75 million including investments in new
    retail stores, IT and manufacturing capacity
  • Weighted average diluted shares outstanding of 112.4 million shares
  • An effective annual tax rate approximately in-line with fiscal 2019

Over the next three fiscal years, the Company currently expects the
following:

  • Average annual revenue growth of at least 20%
  • Annual adjusted EBIT margin expansion of at least 100 basis points in
    fiscal 2022, relative to fiscal 2019
  • Average annual growth in adjusted net income per diluted share of at
    least 25%

The long-term outlook assumes, among other things, a continuation of
current economic conditions and execution of the growth strategies
outlined under the heading “Business Overview” in our Annual Report on
Form 20-F for the fiscal year ended March 31, 2019.

The fiscal 2020 and long-term outlooks above constitute forward-looking
statements and forward-looking information within the meaning of
applicable securities laws (see “Cautionary Note Regarding
Forward-Looking Statements”). Actual results could vary materially as a
result of numerous factors, including certain risk factors, many of
which are beyond the Company’s control. The purpose of our fiscal 2020
and long-term outlook is to provide a description of management’s
expectations regarding the Company’s financial performance and may not
be appropriate for other purposes.

Advertisement
Stake.com

Refinancing

On May 10, 2019, the Company refinanced its debt to support the growth
of the business and enhance financial flexibility. The capacity of the
existing Revolving Facility was increased to $300.0m, with a seasonal
increase to up to $350.0m during peak working capital periods, and the
maturity was extended to June of 2024. Concurrently, the maturity of the
existing USD $113.8m Term Loan Facility was extended to December of
2024. Further details regarding the refinancing are provided in
Management’s Discussion and Analysis in the Annual Report.

Conference Call Information

A conference call to discuss fiscal 2019 results is scheduled for today,
May 29, 2019 at 9:00 a.m. Eastern Time. Dani Reiss, President and Chief
Executive Officer and Jonathan Sinclair, EVP and Chief Financial
Officer, will host the conference call. Those interested in
participating in the call are invited to dial (844) 579-6824 or (763)
488-9145 if calling internationally. Please dial in approximately 10
minutes prior to the start of the call and reference Conference ID
2849456 when prompted. A live audio webcast of the conference call will
be available online at http://investor.canadagoose.com.

About Canada Goose

Advertisement
Stake.com

Founded in a small warehouse in Toronto, Canada in 1957, Canada Goose
has grown into one of the world’s leading makers of performance luxury
apparel. Every collection is informed by the rugged demands of the
Arctic and inspired by relentless innovation and uncompromised
craftsmanship. From the coldest places on Earth to global fashion
capitals, people are proud to wear Canada Goose products. Employing more
than 3,900 people worldwide, Canada Goose is a recognized leader for its
Made in Canada commitment, and is a long-time partner of Polar Bears
International. Visit canadagoose.com for more information.

Non-IFRS Financial Measures

This press release includes references to adjusted net income, EBIT,
adjusted EBIT, adjusted EBIT margin, EBITDA, adjusted EBITDA, adjusted
EBITDA margin, and adjusted net income per share and per diluted share.
The Company presents these measures because its management uses these as
supplemental measures in assessing its operating performance, and
believes they are helpful to investors, securities analysts and other
interested parties, in evaluating the Company’s performance. The
measures referenced above are not measurements of financial performance
under IFRS and they should not be considered as alternatives to measures
of performance derived in accordance with IFRS. In addition, these
measures should not be construed as an inference that the Company’s
future results will be unaffected by unusual or non-recurring items.
These measures have limitations as analytical tools, and you should not
consider such measures either in isolation or as substitutes for
analyzing the Company’s results as reported under IFRS.

This press release also includes reference to constant currency revenue.
The Company presents this measure because we use constant currency
information to provide a framework in assessing how our business
segments performed excluding the effects of foreign currency exchange
rate fluctuations and believe this information is useful to investors to
facilitate comparisons of operating results and better identify trends
in our businesses. The constant currency measure is calculated by
translating the prior year reported amounts into comparable amounts
using a single foreign exchange rate for each currency calculated based
on the current period exchange rates as measured by the Bank of Canada.

The Company’s definitions and calculations of these measures are not
necessarily comparable to other similarly titled measures used by other
companies. These non-IFRS financial measures are defined and reconciled
to the most comparable IFRS measures in the tables at the end of this
press release.

Advertisement
Stake.com

A reconciliation of projected adjusted EBIT, and adjusted net income,
which are forward-looking measures that are not prepared in accordance
with IFRS, to the most directly comparable IFRS financial measures, is
not provided because we are unable to provide such reconciliation
without unreasonable effort. The inability to provide a quantitative
reconciliation is due to the uncertainty and inherent difficulty
predicting the occurrence, the financial impact and the periods in which
the components of the applicable IFRS measures and non-IFRS adjustments
may be recognized. The IFRS measures may include the impact of such
items as non-cash share-based compensation, revaluation of the carrying
value of our indebtedness, amortization of intangible assets and the tax
effect of such items, in addition to other items we have historically
excluded from adjusted EBIT (or adjusted EBITDA) and adjusted net
income. We expect to continue to exclude these items in future
disclosures of these non-IFRS measures and may also exclude other
similar items that may arise in the future (collectively, “non-IFRS
adjustments”). The decisions and events that typically lead to the
recognition of non-IFRS adjustments are inherently unpredictable as to
if or when they may occur. As such, for our fiscal 2020 outlook, we have
not included estimates for these items and are unable to address the
probable significance of the unavailable information, which could be
material to future results.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use of
words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,”
“believe,” “estimate,” “forecast,” “goal,” “project,” and other words of
similar meaning. These forward-looking statements address various
matters including our outlook for fiscal 2020 and our long-term outlook,
related assumptions, and our plans for strategic investments to support
future growth. Each forward-looking statement contained in this press
release is subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such
statement. Applicable risks and uncertainties include, among others, our
expectations regarding industry trends, our business plan and growth
strategies, our expectations regarding seasonal trends, our inventory
levels ahead of these seasonal trends, our ability to implement our
growth strategies, our ability to keep pace with changing consumer
preferences, our ability to maintain the strength of our brand and
protect our intellectual property, as well as the risks identified under
the heading “Risk Factors” in our Annual Report on Form 20-F for the
fiscal year ended March 31, 2019, and filed with the Securities and
Exchange Commission (“SEC”), and the securities commissions or similar
securities regulatory authorities in each of the provinces and
territories of Canada (“Canadian securities regulatory authorities”), as
well as the other information we file with the SEC and Canadian
securities regulatory authorities. We caution investors not to rely on
the forward-looking statements contained in this press release when
making an investment decision in our securities. The forward-looking
statements in this press release speak only as of the date of this
release, and we undertake no obligation to update or revise any of these
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. You are encouraged to
read our filings with the SEC, available at www.sec.gov,
and our filings with Canadian securities regulatory authorities
available at www.sedar.com
for a discussion of these and other risks and uncertainties. Investors,
potential investors, and others should give careful consideration to
these risks and uncertainties.
 

Consolidated Statements of Income and Comprehensive Income

(in millions of Canadian dollars, except share and per share
amounts)

Advertisement
Stake.com
 
   

Three months ended
March 31

 

Year ended
March 31

  2019   2018   2019   2018
$   $ $   $
Revenue 156.2 124.8 830.5 591.2
Cost of sales   53.8     46.6     313.7     243.6  
Gross profit 102.4 78.2 516.8 347.6
Gross margin 65.6 % 62.7 % 62.2 % 58.8 %
Selling, general and administrative expenses 85.0 60.9 302.1 200.1
SG&A expenses as % of revenue 54.4 % 48.8 % 36.4 % 33.8 %
Depreciation and amortization   5.7     2.5     18.0     9.4  
Operating income 11.7 14.8 196.7 138.1
Operating income as % of revenue 7.5 % 11.9 % 23.7 % 23.4 %
Net interest and other finance costs   3.1     2.8     14.2     12.9  
Income before income taxes 8.6 12.0 182.5 125.2
Income tax (recovery) expense (0.4 ) 3.9 38.9 29.1
Effective tax rate   (5.1 )%   32.7 %   21.3 %   23.3 %
Net income 9.0 8.1 143.6 96.1
Other comprehensive (loss) income   (3.0 )   (1.4 )   0.7     (1.8 )
Total comprehensive income   6.0     6.7     144.3     94.3  
Earnings per share
Basic $ 0.08 $ 0.08 $   1.31 $ 0.90
Diluted $ 0.08 $ 0.07 $ 1.28 $ 0.86

Weighted average number of shares
outstanding

Basic 109,867,553 108,074,609 109,422,574 107,250,039
Diluted 111,606,200 111,629,427 111,767,584 111,519,238
Other data: (1)
Adjusted net income 10.0 10.0 151.6 94.1
Adjusted net income per share $ 0.09 $ 0.09 $ 1.39 $ 0.88
Adjusted net income per diluted share $ 0.09 $ 0.09 $ 1.36 $ 0.84
EBITDA 19.1 19.7 219.4 152.3
Adjusted EBITDA 20.4 21.8 229.6 149.2
 

(1) Adjusted net income, adjusted net income per
share and per diluted share, EBITDA, and adjusted EBITDA are non-IFRS
financial measures. See “Reconciliation of Non-IFRS Financial Measures”
for a description of these measures and a reconciliation to the nearest
IFRS measure.
 
Consolidated Statements of Financial Position
As at March 31

(in millions of Canadian dollars)

Advertisement
Stake.com
 
  2019   2018
Assets $   $
Current assets
Cash 88.6 95.3
Trade receivables 20.4 11.9
Inventories 267.3 165.4
Income taxes receivable 4.0 5.1
Other current assets 32.9     23.3
Total current assets 413.2 301.0
 
Deferred income taxes 12.2 3.0
Property, plant and equipment 84.3 60.2
Intangible assets 155.6 136.8
Other long-term assets 7.0 2.1
Goodwill 53.1     45.3
Total assets 725.4     548.4
 
Liabilities
Current liabilities
Accounts payable and accrued liabilities 110.4 109.6
Provisions 8.1 6.3
Income taxes payable 18.1     17.7
Total current liabilities 136.6 133.6
 
Provisions 14.7 10.8
Deferred income taxes 16.7 13.3
Revolving facility
Term loan 145.2 137.1
Other long-term liabilities 13.1     10.0
Total liabilities 326.3 304.8
 
Shareholders’ equity 399.1     243.6
Total liabilities and shareholders’ equity 725.4     548.4
 
 
Consolidated Statements of Cash Flows

(in millions of Canadian dollars)

   

For the three months
ended
March 31

For the year ended
March 31

2019   2018   2019   2018
$   $ $   $
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income 9.0 8.1 143.6 96.1
Items not affecting cash:
Depreciation and amortization 7.4 4.9 22.7 14.2
Income tax (recovery) expense (0.4 ) 3.9 38.9 29.1
Interest expense 2.9 2.6 13.7 12.5
Unrealized foreign exchange (gain) loss (0.2 ) 2.7 (8.6 )
Share-based compensation 1.1 0.6 3.8 2.0
Loss on disposal of assets 0.2     0.2     0.2     0.2  
20.0 20.3 225.6 145.5
Changes in non-cash operating items (13.8 ) 22.1 (100.7 ) (2.3 )
Income taxes paid (5.1 ) (2.5 ) (41.0 ) (7.4 )
Interest paid (2.1 )   (1.9 )   (10.5 )   (9.6 )
Net cash (used in) from operating activities (1.0 )   38.0     73.4     126.2  
 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment (8.9 ) (6.2 ) (30.3 ) (26.1 )
Investment in intangible assets (5.4 ) (1.1 ) (19.0 ) (7.7 )
Business combination (0.2 )       (33.6 )   (0.6 )
Net cash used in investing activities (14.5 )   (7.3 )   (82.9 )   (34.4 )
 
CASH FLOWS FROM FINANCING ACTIVITIES:
Net borrowings (repayment) on revolving facility 0.1 (8.8 )
Deferred financing fees 0.1 (0.3 )
Exercise of stock options 0.6     0.6     3.1     1.2  
Net cash from (used in) financing activities 0.6     0.8     3.1     (7.9 )
Effects of foreign currency exchange rate changes on cash 1.2     1.7     (0.3 )   1.7  
(Decrease) increase in cash (13.7 ) 33.2 (6.7 ) 85.6
 
Cash, beginning of period 102.3     62.1     95.3     9.7  
Cash, end of period 88.6     95.3     88.6     95.3  
 

Contacts

ICR, Inc.
Investors:
Allison Malkin/Caitlin Churchill
(203)
682-8200
Allison.Malkin@ICRinc.com/Caitlin.Churchill@ICRinc.com

Advertisement
Stake.com

or

Media:
Jessica Liddell/Julia Young
646-277-1280
Jessica.Liddell@ICRinc.com/Julia.Young@ICRinc.com

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania